• KOL
    • Hepatocellular Carcinoma
    • Myron Eliot Schwartz
    • Myron Eliot Schwartz: Influence Statistics

      Myron Eliot Schwartz

      Myron Eliot Schwartz

      Show email address

      Surgery. | Department of Surgery, Tisch Cancer Institute, Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, New York, USA | Mount Sinai Liver Cancer ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Myron Eliot Schwartz:Expert Impact

      Concepts for whichMyron Eliot Schwartzhas direct influence:Hepatocellular carcinoma,Liver transplantation,Hepatocellular carcinoma hcc,Intrahepatic cholangiocarcinoma,Liver transplant,Milan criteria,Liver resection,Patients hcc.

      Myron Eliot Schwartz:KOL impact

      Concepts related to the work of other authors for whichfor which Myron Eliot Schwartz has influence:Hepatocellular carcinoma,Liver transplantation,Hcc patients,Transarterial chemoembolization,Milan criteria.

      KOL Resume for Myron Eliot Schwartz

      Year
      2022

      Surgery.

      Department of Surgery, Tisch Cancer Institute, Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, New York, USA

      2021

      Medicine, Icahn School of Medicine at Mount Sinai.

      Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

      Liver Cancer Program, Division of Liver Diseases and RM Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

      Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY

      2020

      Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

      Recanti/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

      Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

      2019

      Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, USA

      Liver Cancer Program, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York

      2018

      Department of Surgery, Icahn School of Medicine at Mount Sinai Medical Center, New York, NY

      Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

      2017

      Mount Sinai Liver Cancer Program, (Divisions of Liver Diseases, Hematology and Medical Oncology, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA

      2016

      Icahn School of Medicine at Mount Sinai, New York, NY

      United States

      2015

      Recanati/Miller Transplantation Institute Icahn School of Medicine at Mount Sinai Department of Surgery New York New York

      2014

      Mount Sinai Medical Center Recanati/Miller Transplantation Institute New York NY USA

      2013

      Department of Surgery, Mount Sinai Medical Center, New York, NY, USA

      Liver Cancer Program, Mount Sinai Medical Center, New York, NY

      2012

      Mount Sinai Medical Center Division of Surgical Oncology Department of Surgery New York NY USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Myron Eliot Schwartz is among the top experts in the world.
      Concept World rank
      10 hcc patients #1
      daclizumab lowdose tacrolimus #1
      longterm nivolumab therapy #1
      72 patients recurrence #1
      cells postoperative day #1
      thinslice ssfse imaging #1
      icc cholangiocarcinoma embolization #1
      cns complications olt #1
      prevalence osteomyelitis #1
      histological tare #1
      shorter survival retransplantation #1
      peritoneal hcc crs #1
      independent predictors pbt #1
      function daclizumab #1
      etiologies hcc #1
      43 biliary complications #1
      ischemia hcc recurrence #1
      96 patients hepatitis #1
      iri large cohort #1
      peritoneal hcc #1
      ltlisted #1
      disease progression pve #1
      icc hcccc #1
      complaints occurred #1
      rejection 25 patients #1
      comparison tace #1
      recurrence hepatocellular cancer #1
      mri actual weights #1
      cca surgical resection #1
      distal artery ligation #1
      recurrence rate 8 #1
      tumour tumour size #1
      vwf caval effluent #1
      thrombomodulin levels 20 #1
      recist icc #1
      true precursors #1
      pediatric donors difference #1
      norms donors #1
      recurrence independent predictors #1
      sibling ldlt #1
      ebv hcc cases #1
      evidence architectural atypia #1
      recurrent hepatitis retransplantation #1
      hepatocellular carcinoma ebv #1
      dcp donor #1
      complications rlv #1
      iri hcv #1
      ≤5 intrahepatic cholangiocarcinoma #1
      multimodal adjuvant therapy #1
      prophylactic interferon #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Myron Eliot Schwartz

      KOL-Index: 23491

      BACKGROUND: Patients undergoing liver transplantation for hepatocellular carcinoma within the Milan criteria (single tumour

      Known for Milan Criteria | Hepatocellular Carcinoma | Liver Transplantation | Microvascular Invasion | 5year Survival
      KOL-Index: 18722

      Background: We reviewed our experience in patients with hepatocellular carcinoma (HCC) and chronic hepatitis to determine if differences exist in preoperative status and postoperative survival between those with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections.Methods: We reviewed the records of 240 consecutive patients with HCC who underwent hepatic resection or liver transplantation at Mount Sinai Hospital between February 1990 and February 1998. Patients who tested ...

      Known for Patients Hbv | Hepatocellular Carcinoma | Chronic Hepatitis | Hcc Hcv | Surgical Outcomes
      KOL-Index: 16559

      BACKGROUND & AIMS: Whether perioperative blood transfusions (PBTs) negatively impact oncologic outcomes after curative resection for HCC remains controversial. We aimed to identify the independent predictive factors of PBT for curative resection of hepatocellular carcinoma (HCC), and to investigate the impact of PBT on long-term recurrence and survivals after resection.

      METHODS: Of 1103 patients who underwent curative liver resection for HCC between 1999 and 2010, 285 (25.8%) patients ...

      Known for Curative Resection | Pbt Rfs | Hepatocellular Carcinoma | Score Matching | Blood Transfusion
      KOL-Index: 16538

      OBJECTIVE: Compare surgical outcomes for hepatitis B virus (HBV)-hepatocellular carcinoma (HCC) versus hepatitis C virus (HCV)-hepatocellular carcinoma (HCC).

      BACKGROUND: HCC is the second leading cause of death from cancer worldwide and is associated with hepatitis virus infection in 80% of cases.

      METHODS: Between 1997 and 2011, 1008 patients with hepatitis B (HBV, n = 431) or hepatitis C (HCV, n = 577) underwent resection (n = 567) or transplantation (n = 441). Resection was indicated ...

      Known for Surgical Outcomes | Patients Hbv | Resection Transplantation | Chronic Hepatitis | Survival Recurrence
      KOL-Index: 15476

      Very little is known about the natural history, effects of therapy, and survival after recurrence of hepatocellular carcinoma (HCC) after liver transplantation. All adult patients undergoing liver transplant from September 19, 1988, until September 19, 2002, were reviewed. Only patients with histologically proven HCC in the explant who subsequently developed recurrence were included in further analysis. The endpoints analyzed were survival from time of transplant and survival from time ...

      Known for Liver Transplant | Survival Recurrence | Hepatocellular Carcinoma | Multivariate Analysis | Local Predictive
      KOL-Index: 15304

      BACKGROUND/AIMS: The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models.

      METHODS: Gene expression (qRT-PCR, oligonucleotide microarray), DNA copy number changes (SNP-array), methylation of tumor ...

      Known for Combined Sorafenib | Liver Neoplasms | Hepatocellular Carcinoma | Combination Rapamycin | Hcc Ras
      KOL-Index: 14692

      BACKGROUND & AIMS: Alpha-fetoprotein (AFP) is widely used as a surveillance test for hepatocellular carcinoma (HCC) among patients with cirrhosis. Des-gamma carboxy-prothrombin (DCP) and lectin-bound AFP (AFP-L3%) are potential surveillance tests for HCC. The aims of this study were to determine performance of DCP and AFP-L3% for the diagnosis of early HCC; whether they complement AFP; and what factors affect DCP, AFP-L3%, or AFP levels.

      METHODS: We conducted a large phase 2 biomarker ...

      Known for Hepatocellular Carcinoma | Early Hcc | Dcp Afp | United States | 95 Sensitivity
      KOL-Index: 14246

      BACKGROUND AND AIMS: Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3%) has been reported to be useful in the early detection of hepatocellular carcinoma (HCC) in Japan. The aim of this prospective study was to compare the clinical utility of AFP-L3% with that of total AFP in North American patients.

      METHODS: Patients with chronic hepatitis (CH) C virus-related cirrhosis from 7 clinical sites were prospectively followed every 3-6 months for 2 yr.

      RESULTS: Of the ...

      Known for Clinical Utility | Hcc Afp | Liver Neoplasms | United States | Early Detection
      KOL-Index: 14106

      Objective. —The prevalence of osteomyelitis in diabetic foot ulcers is unknown. Early diagnosis of this infection is critical, as prompt antibiotic treatment decreases the rate of amputation. We therefore assessed the prevalence of osteomyelitis in 35 diabetic patients with 41 foot ulcers. We compared results of roentgenograms, leukocyte scans with indium In 111 oxyquinoline, and bone scans with the diagnostic criterion standards of bone histologic and culture findings. Leukocyte scans ...

      Known for Foot Ulcers | Osteomyelitis Diabetic Patients | Antibiotic Treatment | Bone Biopsy | Leukocyte Scan
      KOL-Index: 14029

      The design of clinical trials in hepatocellular carcinoma (HCC) is complex because many patients have concurrent liver disease, which can confound the assessment of clinical benefit. There is an urgent need for high-quality trials in this disease. An expert panel was convened by the American Association for the Study of Liver Diseases to develop guidelines that provide a common framework for designing trials to facilitate comparability of results. According to these guidelines, ...

      Known for Hepatocellular Carcinoma | Topic Clinical Trials | Clinical Hcc | Liver Function | Phase Iii
      KOL-Index: 13871

      BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma.

      METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not ...

      Known for Hepatocellular Carcinoma | Sorafenib Placebo | Patients Median Survival | Radiologic Progression | Preliminary Study
      KOL-Index: 13846

      OBJECTIVE: To determine the long-term results of liver transplantation for hepatocellular carcinoma (HCC) measuring 5 cm or larger treated in a multimodality adjuvant protocol.

      SUMMARY BACKGROUND DATA: Transplant has been established as a viable treatment of HCC measuring less than 5 cm, but the results for larger tumors have been disappointing. Several studies have shown promising preliminary results when combining transplant with preoperative transarterial chemoembolization and/or ...

      Known for Liver Transplantation | Adjuvant Therapy | Hepatocellular Carcinomas | Patients Tumors | 5 Years
      KOL-Index: 13702

      BACKGROUND & AIMS: Des-gamma-carboxy prothrombin (DCP) and Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) are surveillance markers used to detect hepatocellular carcinoma (HCC) in Japan. This study evaluated their utility, alone or in combination, in a North American population.

      METHODS: Patients with hepatitis C virus-related cirrhosis were followed up prospectively for 2 years.

      RESULTS: Of 372 patients, HCC developed in 34 of 298 who were free of HCC at ...

      Known for Hepatocellular Carcinoma | Afp Levels | Dcp Hcc | Lens Culinaris | Carboxy Prothrombin
      KOL-Index: 12975

      OBJECTIVE: To summarize the evolution of a living donor liver transplant program and the authors' experience with 109 cases.

      SUMMARY BACKGROUND DATA: The authors' institution began to offer living donor liver transplants to children in 1993 and to adults in 1998.

      METHODS: Donors were healthy, ages 18 to 60 years, related or unrelated, and ABO-compatible (except in one case). Donor evaluation was thorough. Liver biopsy was performed for abnormal lipid profiles or a history of significant ...

      Known for Donor Liver | 1 Year | Bile Leaks | Graft Survival | Center Experience

      Key People For Hepatocellular Carcinoma

      Top KOLs in the world
      #1
      Jordi Bruix
      hepatocellular carcinoma liver transplantation patients hcc
      #2
      Josep María Llovet
      hepatocellular carcinoma advisory consultancy liver transplantation
      #3
      Vincenzo Mazzaferro
      hepatocellular carcinoma liver transplantation patients hcc
      #4
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #5
      Jacques Ferlay
      cancer incidence global burden latin america
      #6
      Hashem B EL‐SERAG
      united states hepatocellular carcinoma veterans affairs

      Surgery. | Department of Surgery, Tisch Cancer Institute, Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, New York, USA | Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of M

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.